New drug combo for lymphoma in the brain
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests combining a targeted drug (orelabrutinib) with standard chemo (R-CHOP plus methotrexate or thiotepa) for people whose DLBCL has spread to the brain or spinal cord. The goal is to see if this combination works better against hard-to-treat lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has spread to your brain or spinal cord.
- You should be between 14 and 80 years old.
- Your liver, kidneys, and bone marrow must be working fairly well (based on blood tests).
- You cannot have a serious heart condition, active hepatitis or HIV, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
This trial tests whether adding the drug zanubrutinib to standard chemotherapy can better treat newly diagnosed diffuse large B-cell lymphoma that has spread to the central nervous system. It is for patients whose lymphoma is identified by a specific molecular subtype or by positive findings in the spinal fluid or brain scans.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests a new combination of drugs for people newly diagnosed with an aggressive type of lymphoma called diffuse large B-cell lymphoma (DLBCL). The combo includes orelabrutinib plus standard chemo-immunotherapy, and may help improve outcomes for those at intermediate or high risk.
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
Hear when a new CNS Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.